The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis
Obesity Reviews · 2024
DOI: 10.1111/obr.13686 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity Reviews, 2024. Verfasst von Jian-Ying Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Pediatric Obesity. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Growing evidence indicates that incretin‐based therapies (IBTs), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), and dipeptidyl peptidase‐4 inhibitors (DPP4is) are effective and safe for treating pediatric obesity patients with or without type 2 diabetes. Therefore, we aimed to perform a systematic review and meta‐analysis for updating current evidence.
Methods
We searched the PubMed, the Cochrane Library, and the EMBASE database for articles published until September 15, 2023, and limited to randomized control trials. The primary outcomes were changed from baseline in weight metrics and the cardiometabolic profile. A random effects model will be used, as high heterogeneity is expected. All analyses were performed using STATA 17.0.
Results
Fifteen trials with a total number of 1286 participants were included in our meta‐analysis. Overall, the mean difference in weight change between the IBTs group and the control group was −2.89 kg (95% confidence interval, −5.12 to −0.65, p = 0.011). Additionally, IBTs significantly reduced the HbA 1c level and fasting plasma glucose by 0.37% and 6.99 mg/dl, compared with control groups. IBTs showed a little increased risk of GI side effects and hypoglycemia events, but none of the severe hypoglycemia events were occurred in IBTs group.
Conclusions
Our study results have proved that GLP‐1 RAs are safe, acceptable, and effective in weight reduction and sugar control for children with obesity. In addition, DPP‐4is seems to have no effect on glycemic control and weight loss in childhood obesity. Further research is needed to confirm these findings, especially in younger children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan.
- Department of Pharmacy, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
- Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
- Department of Pharmacy, Ministry of Health and Welfare Taipei Hospital, New Taipei City, Taiwan.
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Nursing, Cardinal Tien College of Healthcare and Management, Taipei, Taiwan.
ORCID-Profile: Ming-Chia Lee
Zitieren
APA
Wang, J. Y., Kang, J. W., Wu, C. Y., Peng, T. R., Liao, L. M., Lee, M. C., Lee, J. A., & Chen, S. M. (2024). The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis. Obesity Reviews. https://doi.org/10.1111/obr.13686
Vancouver
Wang JY, Kang JW, Wu CY, Peng TR, Liao LM, Lee MC, et al. The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis. Obesity Reviews. 2024. doi:10.1111/obr.13686
BibTeX
@article{Wang2024,
author = {Wang, Jian-Ying and Kang, Jyun-Wei and Wu, Chih-Yuan and Peng, Tzu-Rong and Liao, Ling-Mei and Lee, Ming-Chia and Lee, Jen-Ai and Chen, Shih-Ming},
title = {The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta‐analysis},
journal = {Obesity Reviews},
year = {2024},
doi = {10.1111/obr.13686}
}
EUVIMED